Study will help with the development of a companion test for Lilly’s Xigris.
Sirius Genomics signed an agreement with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations in severe sepsis patients. This work will help Sirius develop a test to assess responsiveness to recombinant human activated protein C, which is sold by Eli Lilly under the trademark Xigris ®, in patients with severe sepsis at high risk of death.
“Access to AP-HP’s severe sepsis patients will be critical in the validation of Sirius’ sepsis biomarkers,” notes Brad Popovich, Ph.D., president and CEO of Sirius.
In May Sirius entered a deal with Vanderbilt University that would also aid in the development of the Xigris companion diagnostic. The arrangement allows the firm to study patients enrolled in Vanderbilt’s Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study.
